Two More Pairs of Denosumab Biosimilars Enter US Market

Dr Chelsee Jensen Discusses Pricing Strategies for Adalimumab Biosimilars

November 26th 2023

By Skylar Jeremias

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, explains the purpose of dual-pricing strategies for adalimumab biosimilars and predicts whether these strategies will occur in other treatment spaces.

Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

November 25th 2023

By Deana Ferreri, PhD

A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.

The Top 5 Biosimilar Articles for the Week of November 20

November 24th 2023

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of November 20, 2023.

Confusion Persists Around the Interchangeability Designation for Biosimilars

November 23rd 2023

By Gillian Woollett, MA, DPhil

The legal and common uses of “interchangeability” continue to be conflated.

Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar

November 22nd 2023

By Skylar Jeremias

Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).

Evolution of Auto-Substitution in Biosimilar Landscape

November 21st 2023

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Defining Interchangeability and Switching in Biologics

November 21st 2023

Medical experts discuss interchangeability designation requirements for biosimilars.

Study Confirms Safety and Efficacy of Adalimumab Biosimilar HS016 in IBD

November 21st 2023

By Cameron Santoro

A China-based study where data were collected from patients with inflammatory bowel disease (IBD) showed safety and efficacy of the adalimumab biosimilar HS016.

BioRationality: FDA Publishes Results of First Meta-Analysis to Conclude All Biosimilars Are Interchangeable

November 20th 2023

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, offers hope for the end of interchangeability labels in the United States in his latest column.

Global Biosimilars Week: Dr Fran Gregory Explores the Growing Oncology Biosimilar Space, Previews Future

November 19th 2023

By Skylar Jeremias

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, examines the evolution of the oncology biosimilar space in this special episode of Not So Different to close out Global Biosimilars Week 2023.